← All indications
Chondrosarcoma
A slowly growing malignant neoplasm derived from cartilage cells, occurring most frequently in pelvic bones or near the ends of long bones, in middle-aged and old people. Most chondrosarcomas arise de novo, but some may develop in a preexisting benign cartilaginous lesion or in patients with ENCHONDROMATOSIS. (Stedman, 25th ed)
Subtype terms (2)
More specific conditions that are subtypes of Chondrosarcoma in the MeSH hierarchy.
- Chondrosarcoma, Clear Cell
1 drug approved
- Chondrosarcoma, Mesenchymal
8 drugs approved
Drugs by status
Phase 3 trials (4)
Phase 2 trials (36)
- azacitidine
- abemaciclib
- anlotinib
- atezolizumab
- autologous tumor infiltrating lymphocytes
- belinostat
- olutasidenib
- vismodegib
- gemcitabine
- imatinib
- guadecitabine
- aldesleukin
- nivolumab
- saridegib
- regorafenib
- perifosine
- ipilimumab
- ro4929097
- sitagliptin
- sirolimus
- cyclophosphamide
- dasatinib
- everolimus
- angiotensin 1-7
- cabozantinib
- fludarabine
- linsitinib
- chloroquine
- romidepsin
- cisplatin
- +6 more
Phase 1 trials (16)
Other trials (3)
Organizations
Organization Involved with Phase 3 Indications (1)
Organization Involved with Phase 2 Indications (49)
- Celgene
- Bristol-Myers Squibb
- Genentech
- AEterna Zentaris
- GlaxoSmithKline
- Infinity Pharmaceuticals, Inc.
- Concerto HealthAI
- Agios Pharmaceuticals, Inc.
- Forma Therapeutics, Inc.
- PharmaMar
- National Institutes of Health (NIH)
- Javier Martín Broto, M.D.
- Centre Leon Berard
- Cornell University
- Harvard University
- Eastern Cooperative Oncology Group
- Temple University
- Grupo Espanol de Investigacion en Sarcomas
- Hospital Son Espases
- Hospital Universitario Central de Asturias
- Institut Bergonié
- Italian Sarcoma Group
- Medical College of Wisconsin
- Oregon Health and Science University
- Sarcoma Alliance for Research through Collaboration
- Southwest Oncology Group
- Universidad Autonoma de Madrid
- Universidad Complutense de Madrid
- UNICANCER
- University of Miami
- +19 more
Organization Involved with Phase 1 Indications (7)
Organization Involved with Other Experimental Indications (4)